Subacute toxicity of all-trans-retinoic acid loaded biodegradable microspheres in rats

Drug Development Research

Volumn 59, Issue 3, 2003, Pages 326-332

  Choi, Yongdoo ^a   Lee, Chulkyu ^b   Park, Kyeongsoon ^a   Kim, Sang Yoon ^c   Kim, Sun Hee ^d   Han, Shin ^b   Kim, Sung Hyun ^e   Byun, Youngro ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Shinpoong Pharmaceutical Co   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Gwangju Jeonnam Small/Medium Bus A   (South Korea)

Author keywords

All trans retinoic acid; Microsphere; PDLLA; Subacute toxicity

Indexed keywords

MICROSPHERE; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; MALE; NONHUMAN; RAT; TOXICITY;

EID: 0042125582     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10283     Document Type: Article

References (26)

1. Achkar CC, Bentel JM, Boylan JF, Scher HI, Gudas LJ, Miller WH. 1994. Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug Metab Dispos 22:451-458.
2. Buggé CJL, Rodriguez LC, Vane FM, 1985. Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 3:269-277.
3. Choi Y, Kim SY, Kim SH, Lee K-S, Kim C, Byun Y. 2001. Long-term delivery of all-trans-retinoic acid using biodegradable PLLA/ PEG-PLLA blended microspheres. Int J Pharm 215:67-81.
4. Choi Y, Kim SY, Kim SH, Park TG, Moon HT, Byun Y. 2002. In vivo biocompatibility studies of poly(D,L-lactide)/poly(ethylene glycol)-poly(L-lactide) microspheres containing all-trans-retinoic acid. J Biomater Sci Polymer Edn 13:301-322.
5. Cullum ME, Zile MH. 1985. Metabolism of all-trans-retinoic acid and all-trans-retinyl acetate. Demonstration of common physiological metabolites in rat small intestinal mucosa and circulation. J Biol Chem 260:10590-10596.
6. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. 1992. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292-296.
7. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr. 1994. All-trans-retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med 120:278-286.
8. Giannini F, Maestro R, Vukosa T, Vljevic T, Pomponi F, Boiocchi M. 1997. All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: Implications for in vivo retinoic acid use. Int J Cancer 70:194-200.
9. Gillis JC, Goa KL. 1995. Tretinoin: a review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Drugs 50:897-923.
10. Hixson EJ, Denine EP. 1978. Comparative subacute toxicity of all-trans- and 13-cis-retinoic acid in Swiss mice. Toxicol Appl Pharmacol 44:29-40.
11. Hixson EJ, Harrison SD Jr. 1981. Effect of nonsteroidal anti-inflammatory drugs on sublethal retinoic acid toxicity in Swiss mice. Biochem Pharmacol 30:1714-1716.
12. Hixson EJ, Burdeshaw JA, Denine EP, Harrison SD Jr. 1979. Comparative subchronic toxicity of all-trans- and 13-cis-retinoic acid in Spragne-Dawley rats. Toxicol Appl Pharmacol 47:359-365.
13. Kalmekerian GP, Jasti RK, Celano P, Nelkin BD, Marby M. 1994. All-trans retinoic acid alters myc gene expression and inhibits in vitro progression in small-cell lung cancer. Cell Growth Differ 5:55-60.
14. Kurlandsky SB, Gamble MV, Ramakrishnan B, Blaner WS. 1995. Plasma delivery of retinoic acid to tissues in the rat. J Biol Chem. 270:17850-177857.
15. Kurtz PJ, Emmerling DC, Donofrio DJ. 1984. Subchronic toxicity of all-trans-retinoic acid and retinylidene dimedone in sprague-dawley rats. Toxicology 30:115-124.
16. Lopez-Berestein G, Rosenblum M, Sadeghi T, Mehta K. 1994. Pharmacokinetics, tissue distribution, and toxicology of tretinoin incorporated in liposomes. J Liposome Res 4:689-700.
17. Lotan R. 1994. Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res 54:1987-1990.
18. Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrel RP Jr. 1992a. Clinical pharmacology, of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 50:2138-2142.
19. Muindi JR, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr. 1992b. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "Resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303.
20. Parthasarathy R, Mehta K. 1998. Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form. Cancer Lett 134:121-128.
21. Salar A. 2000. Acute hepatomegaly with severe liver toxicity due to all-trans-retinoic acid. Haematologica 85:551-552.
22. Teelmann K. 1983. Comparative toxicity of oral all-trans-retinoic acid and the aromatic retinoids Ro 10-9359 and Ro 12-7554 in rats. Drug Dev Res 3:49-57.
23. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardt L, Palumbo R, Bollag W. 1997. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70:619-627.
24. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon M, Dmitrovsky E. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin. N Engl J Med 324:1385-1393.
25. Wiley JS, Firkin FC. 1995. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 9:774-778.
26. Windhorst DB, Nigra T. 1982. General clinical toxicology of oral retinoids. J Am Acad Dermatol 6:675-682.